T3	eligibility 251 294	Breast cancer patients with bone metastases
T4	intervention-participants 331 334	137
T5	control-participants 379 382	138
T7	outcome-Measure 424 539	mean percentage change in serum levels of cross-linked C-terminal telopeptide of type I collagen (S-CTX) at week 12
T9	outcome 777 782	S-CTX
T10	outcome 897 902	U-CTX
T11	outcome 1120 1141	Bone ALP, PINP and OC
T13	iv-bin-percent 1304 1309	65.0%
T14	cv-bin-percent 1317 1322	75.9%
T15	outcome 1332 1340	days 1-3
T12	outcome 1280 1302	adverse events overall
T16	iv-bin-percent 1342 1346	8.0%
T17	cv-bin-percent 1354 1359	47.5%
T18	outcome 1377 1384	pyrexia
T19	iv-bin-percent 1404 1406	0%
T20	cv-bin-percent 1414 1419	16.8%
T21	outcome 1425 1434	bone pain
T22	iv-bin-percent 1436 1440	5.8%
T23	cv-bin-percent 1448 1453	12.4%
T6	intervention 0 16	Oral ibandronate
T28	control 33 60	intravenous zoledronic acid
T1	outcome 978 997	difference in S-CTX
T2	iv-cont-mean 801 804	76%
T24	iv-cont-sd 809 811	29
T25	cv-cont-mean 845 848	73%
T29	cv-cont-sd 853 855	47
T26	iv-cont-mean 916 919	78%
T30	iv-cont-sd 924 926	50
T27	cv-cont-mean 950 953	86%
T31	cv-cont-sd 958 960	17
T8	outcome-Measure 541 560	Urinary CTX (U-CTX)
T32	outcome-Measure 562 593	bone alkaline phosphatase (ALP)
T33	outcome-Measure 595 679	amino-terminal procollagen propeptide of type I collagen (PINP) and osteocalcin (OC)
